Search Results - "Flochova, Emilia"

Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial by Greil, Richard, Obrtlikova, Petra, Smolej, Lukas, Kozak, Tomas, Steurer, Michael, Andel, Johannes, Thaler, Josef, Mikuskova, Eva, Gercheva, Liana, Nösslinger, Thomas, Ladicka, Miriam, Girschikofsky, Michael, Hrubiko, Mikulá, Jäger, Ulrich, Fridrik, Michael A., Pecherstorfer, Martin, Kralikova, Eva, Burcoveanu, Cristina, Goranov, Stefcho, Jurkovikova, Jana, Petzer, Andreas L., Mihaylov, Georgi G., Raynov, Julian, Oexle, Horst, Zabernigg, August, Flochova, Emilia, Palasthy, Stanislav, Melchardt, Thomas, Mayer, Jiri, Egle, Alexander

“…▪ Introduction: Chemoimmunotherapy has become a standard approach in previously untreated and also in pretreated CLL. Addition of Rituximab to FC in fit…”
Get full text

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile by Kreutzman, Anna, Rohon, Peter, Faber, Edgar, Indrak, Karel, Juvonen, Vesa, Kairisto, Veli, Voglová, Jaroslava, Sinisalo, Marjatta, Flochová, Emília, Vakkila, Jukka, Arstila, Petteri, Porkka, Kimmo, Mustjoki, Satu

“…Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-α) was the treatment of choice in chronic myeloid leukemia (CML). Curiously, some…”
Get full text

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile by Kreutzman, Anna, Rohon, Peter, Faber, Edgar, Indrak, Karel, Juvonen, Vesa, Kairisto, Veli, Voglova, Jaroslava, Sinisalo, Marjatta, Flochova, Emilia, Arstila, Petteri, Porkka, Kimmo, Mustjoki, Satu

“…Abstract 1201 Before the era of tyrosine kinase inhibitors (TKIs), interferon alpha (IFN-α) was the treatment of choice in CML and prolonged survival of…”
Get full text

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial by Egle, Alexander, Melchardt, Thomas, Obrtlíková, Petra, Smolej, Lukáš, Kozák, Tomáš, Steurer, Michael, Andel, Johannes, Burgstaller, Sonja, Mikušková, Eva, Gercheva, Liana, Nösslinger, Thomas, Papajík, Tomáš, Ladická, Miriam, Girschikofsky, Michael, Hrubiško, Mikuláš, Jäger, Ulrich, Voskova, Daniela, Pecherstorfer, Martin, Králiková, Eva, Burcoveanu, Christina, Spasov, Emil, Petzer, Andreas, Mihaylov, Georgi, Raynov, Julian, Oexle, Horst, Zabernigg, August, Flochová, Emília, Palášthy, Stanislav, Stehlíková, Olga, Doubek, Michael, Altenhofer, Petra, Weiss, Lukas, Magnes, Teresa, Pleyer, Lisa, Klingler, Anton, Mayer, Jiří, Greil, Richard

“…No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for…”
Get full text

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial by Greil, Richard, Prof, Obrtlíková, Petra, MD, Smolej, Lukáš, MD, Kozák, Tomáš, Prof, Steurer, Michael, Prof, Andel, Johannes, MD, Burgstaller, Sonja, MD, Mikušková, Eva, MD, Gercheva, Liana, Prof, Nösslinger, Thomas, MD, Papajík, Tomáš, Prof, Ladická, Miriam, MD, Girschikofsky, Michael, MD, Hrubiško, Mikuláš, Prof, Jäger, Ulrich, Prof, Fridrik, Michael, MD, Pecherstorfer, Martin, Prof, Králiková, Eva, MD, Burcoveanu, Cristina, MD, Spasov, Emil, MD, Petzer, Andreas, Prof, Mihaylov, Georgi, MD, Raynov, Julian, MD, Oexle, Horst, MD, Zabernigg, August, MD, Flochová, Emília, MD, Palášthy, Stanislav, MD, Stehlíková, Olga, Doubek, Michael, Prof, Altenhofer, Petra, MD, Pleyer, Lisa, MD, Melchardt, Thomas, MD, Klingler, Anton, PhD, Mayer, Jiří, Prof, Egle, Alexander, MD

“…Summary Background In many patients with chronic lymphocytic leukaemia requiring treatment, induction therapy with rituximab plus chemotherapy improves…”
Get full text

C0173 High levels of von Willebrand factor antigen and procoagulant factor VIII found in multiple myeloma patients are associated with activity status by Sokol, Juraj, Flochová, Emília, Chudej, Juraj, Šimonová, Radoslava, Chudá, Daniela, Chudý, Peter, Staško, Ján, Kubisz, Peter

Get full text

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-[alpha] Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile by Kreutzman, Anna, Rohon, Peter, Faber, Edgar, Indrak, Karel, Juvonen, Vesa, Kairisto, Veli, Voglová, Jaroslava, Sinisalo, Marjatta, Flochová, Emília, Vakkila, Jukka, Arstila, Petteri, Porkka, Kimmo, Mustjoki, Satu

“…Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-[alpha]) was the treatment of choice in chronic myeloid leukemia (CML). Curiously,…”
Get full text